派格生物医药-B(02565)今日盘中大涨10.69%，引起了市场的广泛关注。
消息面上，公司基石投资者同意自愿延长禁售期，从原定届满日起至5月20日不会减持任何持股。公司表示，此举表明基石投资者基于公司在技术研发能力及重大临床里程碑方面取得的进展，对公司的未来前景充满信心。
此外，派格生物的核心管线CR059入选美国糖尿病协会科学年会Late Breaking Abstract，再度将市场目光聚焦于其circRNA-LNP技术平台。作为专注于代谢疾病领域的创新药企业，CR059所代表的超长效GLP-1技术路径，正在为市场带来新的想象空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.